"We believe that by successfully executing on our plans, Orexigen can achieve profitability beginning in full year 2019 and that the capital we raised in March in connection with the Contrave acquisition will be sufficient to get us there," Narachi said.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.